Rare Immune-Related Adverse Events (irAEs): Approach to Diagnosis and Management
A Javaid, C Bennett, A Rao, L Spain - Pharmaceutical Medicine, 2024 - Springer
Immune checkpoint inhibitors (ICIs) have revolutionised the treatment landscape across
many solid organ malignancies and form part of routine clinical practice in many tumours. As …
many solid organ malignancies and form part of routine clinical practice in many tumours. As …
Clinical Association Between Immune-related Adverse Events and Treatment Efficacy in Patients With Non-small-cell Lung Cancer Treated With Nivolumab …
N Ebi, H Inoue, F Igata, R Okuma, E Kinoshita… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: Nivolumab and ipilimumab combination therapy has been extensively
explored for the treatment of advanced non-small-cell lung cancer (NSCLC) through the …
explored for the treatment of advanced non-small-cell lung cancer (NSCLC) through the …
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma …
Y Zhang, J Chen, H Liu, J Dai, J Zhao, S Zhu… - Cancer Treatment …, 2024 - Elsevier
Background This study aimed to summarize the occurrence of immune-related adverse
events (irAEs) and further evaluate their association with clinical outcomes in patients with …
events (irAEs) and further evaluate their association with clinical outcomes in patients with …